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Abstract
Global DNA hypomethylation is a hallmark of cancer cells, but its molecular mechanisms have not been elucidated. Here, we
show that the disruption of Dnmt1/PCNA/UHRF1 interactions promotes a global DNA hypomethylation in human gliomas.
We then demonstrate that the Dnmt1 phosphorylations by Akt and/or PKC abrogate the interactions of Dnmt1 with PCNA
and UHRF1 in cellular and acelluar studies including mass spectrometric analyses and the use of primary cultured patient-
derived glioma. By using methylated DNA immunoprecipitation, methylation and CGH arrays, we show that global DNA
hypomethylation is associated with genes hypomethylation, hypomethylation of DNA repeat element and chromosomal
instability. Our results reveal that the disruption of Dnmt1/PCNA/UHRF1 interactions acts as an oncogenic event and that
one of its signatures (i.e. the low level of mMTase activity) is a molecular biomarker associated with a poor prognosis in GBM
patients. We identify the genetic and epigenetic alterations which collectively promote the acquisition of tumor/glioma
traits by human astrocytes and glial progenitor cells as that promoting high proliferation and apoptosis evasion.
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Introduction
The low level of DNA methylation in tumors compared to the
level of DNA methylation in their normal-tissue counterparts or
global DNA hypomethylation was one of the first epigenetic
alterations to be found in human cancer [1,2]. While the
contribution of genome hypomethylation in cancer development
and progression is explained by several mechanisms: chromosomal
instability, loss of imprinting, and reactivation of transposable
elements [3,4], the molecular causes of genome hypomethylation
remain unclear. Indeed, despite the central roles of the DNA
methyltransferases (Dnmts) in the establishment and maintenance of
the DNA methylation, no clear consensus appears between the
reduction of theDnmtsexpression andthe genome hypomethylation
in human cancers [5]. Nevertheless, the cancer-associated genome
hypomethylationcouldbeexplainedbythedisruptionofinteractions
existing between Dnmts and the DNA replication and DNA repair
proteins because these interactions play a crucial role in the DNA
methylation in mammalian cells [6,7,8]. We here demonstrate that
the disruption of the Dnmt1/PCNA/UHRF1 interactions act as
oncogenic event promoting the acquisition by human astrocytes and
glial progenitor cells of hallmarks of cancer such as high proliferation
and apoptosis evasion in a context of genome and gene-specific
hypomethylation and chromosomal instability.
Results
In glioma, the decrease of the mMTase activity is
associated with the degree of DNA hypomethylation and
confers poor prognosis of survival
The global DNA methylation status of glioma was assessed by
measuring the number of 5-methylcytosine (5 mC) in a collection
of 82 surgical resections of glioma and in 5 non-pathological brain
biopsies (Figure 1A). ELISA results indicate that the 5 mC
number decreases when the glioma grade increases indicating that
the genome hypomethylation characterizes the initiation and/or
the development of gliomagenesis (Pearson’s correlation test,
r=20.537, p,0.0001). To identify a molecular cause of global
DNA hypomethylation, we initially searched whether the decrease
of 5 mC number occurring during gliomagenesis is inversely
correlated with the expression level of Dnmt3a and Dnmt3b or
with their methyltransferase (MTase) activity i.e. with the de novo
MTase activity. No significant correlation was reveled by statistical
analysis of these parameters (r=20.155, p=0.1517, r=0.152,
p=0.1599 and r=0.132, p=0.2229, respectively) (Figures 1B
and 1C).
The Dnmt1 being the predominant maintenance methyltrans-
ferase enzyme, we next assessed its expression and its activity (i.e.
the maintenance MTase (mMTase) activity) in glioma biopsies in
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11333order to determine whether the alteration of these parameters
could explain the global DNA hypomethylation seen in glioma.
These analyses indicated that the decrease of 5 mC number
occurring during gliomagenesis is correlated with the decrease of
mMTase activity but not with the variations of the expression level
of the Dnmt1 (r=0.770, p,0.0001 and r=20.131, p=0.2265,
respectively) (Figure 1D).
We then implemented this observation by analyzing whether the
level of mMTase activity could be used as an alternative prognostic
factor in a group of 45 GBM patients for which we obtained a well-
Figure 1. The decrease of maintenance methyltransferase activity (mMTase) is correlated with the genome hypomethylation
occurring during gliomagenesis, and confers poor prognosis in glioma patients. (A) Correlation between the 5-methylcytosine number
(5 mC) and tumor grade in a collection of 82 glioma and 5 non-tumor brain samples (nt). 5 mC was estimated by using the Methylamp Global DNA
Methylation Quantification kit (Epigentek-Euromedex, France). Dotted lines represent the median of each parameter. (B) Correlation study between the
5-methylcytosine number (5 mC) andlevel expression of Dnmt3a(left)andDnmt3b (right). (C) Correlation study between the5-methylcytosine number
(5 mC) and the de novo methyltransferase (dnMTase) calculated by using unmethylated DNA substrates in DMB assays as previously described [32]. (D)
Correlation study between the 5-methylcytosine number (5 mC) and the maintenance methyltransferase (mMTase) calculated by using hemi-
methylated DNA substrates in DMB assays (Top). Correlation study between relative Dnmt1 expression and the 5-methylcytosine number (5 mC)
(bottom). (E) Kaplan-Meier estimates time of survival between patients suffering from glioma presenting a high level of mMTase activity (grey line) and
those whose tumors harbored a low level of mMTase activity (black line). In this figure, e represents 5 non-tumor brain samples, % represents grade II
astrocytomas/oligodendroglioma, n represents grade III astrocytomas/oligodendroglioma, # represents grade IV astrocytomas/GBM.
doi:10.1371/journal.pone.0011333.g001
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mMTase activity levels, the 45 patients were divided into two
subgroups. 23 patients whose glioma presented a low level of mMTase
activity (i.e. equal to or lower than the median value of mMTase
activities) were included in group#1, while 22 patients whose tumors
harbored a high level of mMTase activity (i.e. higher than the median
value of mMTase activities) composed group#2. Survival curves were
estimated by the Kaplan-Meier method and compared with the Cox
proportional hazards survival regression test (Figure 1E). Thus, we
observed a significant difference in survival time between patients who
had a high level of mMTase and those who did not (p=0.0019).
These results indicate that the level of mMTase activity could be used
as a prognostic factor for survival. Moreover, the identification of
molecular mechanisms implicated into the global DNA hypomethyla-
tion via the decrease of mMTase activity would open new and rational
biomarkers for patient selection in anti-glioma therapy and would
identify new therapeutic targets against glioma.
The low level of the Dnmt1/PCNA/UHRF1 interactions is a
molecular hallmark associated with the low degree of
global DNA hypomethylation in glial/glioma cells
To identify the molecular mechanism governing the decrease of
mMTase and conferring the increase of the degree of global DNA
hypomethylation characterizing the human gliomagenesis, we
decided to screen the level of 5 mC, the mMTase activity and the
Dnmt1 expression in a panel of glial/glioma cells including nine
primary cultured tumor cells (PCTC) obtained from glioma of
different grades (3 PCTC per glioma grade), and four glial cell lines
(GCL)inwhichAstro#40representsnontumoralhumanastrocytes
and U251, U87 and LN18 cells represent tumor human glioma cell
lines. Consistently with what we reported about the human biopsies,
ELISA, flow cytometry and DMB assay indicated that the 5 mC
number and the mMTase activity decreased during gliomagenesis
while the Dnmt1 expression remained unchanged (Figure 2A and
Supplemental data S2). In parallel with these results, western
blot realized from chromatin extraction revealed that the decrease
of mMTase activity, seen in glioma, is associated with the decrease
of the Dnmt1 quantity recruited on DNA (Figure 2A).
Literature reporting that PCNA and UHRF1 proteins mediate
the epigenetic inheritance in mammalian cells by recruiting
Dnmt1, we then hypothesized that the defect of Dnmt1
recruitment on DNA could be due to the disruption of interactions
existing between Dnmt1, PCNA and UHRF1 [6,8]. The Dnmt1-
immunoprecipitation indicated that it was the case because the
quantity of PCNA and UHRF1 decreased when the tumor grade
increased while the quantity of Dnmt1 immunoprecipitated
remained unchanged (Figure 2A and Supplemental data
S3). The disruption of the Dnmt1/PCNA interactions is also
confirmed by the use of a proximity ligation in situ assay (P-LISA)
and the significant reduction of the Dnmt1/PCNA interactions in
U251 cells (a glioma cell line) compared with Astro#40 cells (a
non-tumor glial cell lines) (p=0.003) (Figure 2B).
Collectively, all our data identified the disruption of the Dnmt1/
PCNA/UHRF1 interactions as a molecular event associated with
the degree of global DNA hypomethylation in glial/glioma cells.
The phosphorylations of the Dnmt1 at residues
preferentially phosphorylated by Akt and PKC is a
molecular hallmark associated with the low level of the
Dnmt1/PCNA/UHRF1 interactions and with the low degree
of global DNA hypomethylation in glial/glioma cells
In parallel with these results, we noted that the phosphorylation
levels of Dnmt1, at residues preferentially recognized and
phosphorylated by Akt and PKC (pDnmt1-PAS and pDnmt1-
PPCS, respectively), increased when the tumor grade increased
(Figure 3A). In other terms, this result indicated that the levels of
pDnmt1-PAS and pDnmt1-PPCS are inversely correlated with the
level of the Dnmt1-PCNA-UHRF1 interactions. Thus, we
wondered whether these phosphorylations of Dnmt1 are hallmarks
reflecting the level of the Dnmt1-PCNA-UHRF1 interactions in
two cellular systems of study.
By treating the PCTC#IV with Akt and PKC inhibitors, we
firstly demonstrated that the loss of pDnmt1-PAS and pDnmt1-
PPCS is associated with the increase of the Dnmt1-PCNA-
UHRF1 interactions and with the increase of mMTase activity i.e.
of the enzymatic activity mainly catalyzed by the Dnmt1
(Figure 3B).
Secondly, by promoting the activation of Akt and PKC via the
constitutive overexpression of PDGF-B in Ntv-a/RCAS system of
gliomagenesis, we induced the presence of pDnmt1-PAS and
pDnmt1-PPCS and the strong decrease of the Dnmt1-PCNA-
UHRF1 interactions and of the mMTase activity (Figure 3C).
The link between these three events is also supported by the fact
that the treatment of the Ntv-a/PDGF cells with Akt and PKC
inhibitors reduced the presence of pDnmt1-PAS and pDnmt1-
PPCS and restored the Dnmt1-PCNA-UHRF1 interactions
(Figure 3C).
Thus, it seems that, among the pleotropic effects of the PDGF
signaling, the activation of Akt and PKC is the main effect
responsible of the decrease of the mMTase activity. This point is
also supported by the fact that the inhibition of the Ras signaling
pathway (one other major PDGF-induced signaling pathway) in
the Ntv-a/PDGF cells via a farnesylthiosalicylic acid (FTS)
(40 mM) treatment, did not affect the mMTase activity
(p=0.8143) (Supplemental data S4).
Identification and impact of the Akt- or PKC-induced
phosphorylations of the Dnmt1 on its capacity to interact
with PCNA and UHRF1
To identify the amino acid residue phosphorylated by Akt and
PKC, we decided to perform mass spectrometric analysis from
recombinant Dnmt1 protein (Dnmt1
R) phosphorylated by Akt and
PKC. Thus, despite the weak presence of the pDnmt1
S127 into the
Dnmt1
R purified from baculovirus, mass spectrometric analyses
clearly indicated that Akt and PKC phosphorylated the Dnmt1
R
at residues serine-127/143 and serine-127 respectively (Figure 4A
and Supplemental data S6).
According to these data, we synthesized two antibodies directed
againstthe pDnmt1
S127 andpDnmt1
S143 (Proteogenix,France).After
validation of these antibodies by using kinase assays, western blot and
ELISA methods, we decided to use these the antibodies to determine
the impact of the Akt/PKC-induced phosphorylations of Dnmt1 on
the Dnmt1/PCNA and Dnmt1/UHRF1 interactions (Supplemen-
tal data S7 and Supplemental data S8). For this purpose, we
realized pull down and immunoprecipitation experiments.
In pull down experiments, we generated the pDnmt1
S127 and
pDnmt1
S127/S143 proteins by using the recombinant PKC and Akt
kinases (Supplemental data S8). Thus, we noted that the degree
of phosphorylation of Dnmt1 at S127 by PKC decreased the
Dnmt1/UHRF1 interactions without affected the Dnmt1/PCNA
interactions (Figure 4B). The double phosphorylation of Dnmt1 at
S127 and S143 by Akt decreased the Dnmt1/UHRF1 and Dnmt1/
PCNA interactions. No effect of the Akt/PKC-induced phosphor-
ylations of Dnmt1 was observed about the Dnmt1/HDAC1
interactions. Moreover, an ELISA analysis performed with the
pDnmt1
S127 and pDnmt1
S143 antibodies, revealed that the Dnmt1
interacting with GST-UHRF1 was unphosphorylated, that the
DNA Methylation and Glioma
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residus S127, and that the Dnmt1 interacting with GST-HDAC1
can be phosphorylated at residus S127 and/or S143 (Figure 4B).
By performing western blot and immunoprecipitation experi-
ments from Astro#40 and U251 cells, we not detected the
presence of the pDnmt1
S127 and/or pDnmt1
S143 in Astro#40
Figure 2. Disruption of the Dnmt1/PCNA and Dnmt1/UHRF1 interactions in gliomagenesis. (A) 5-methylcytosine (5 mC) number,
maintenance methyltransferase (mMTase) activity, Dnmt1 expression, Dnmt1 recruitment on DNA and Dnmt1/PCNA/UHRF1 interaction in a panel of
PCTC issued from the different grade of glioma. 5 mC was estimated by using the Methylamp Global DNA Methylation Quantification kit (Epigentek-
Euromedex, France). mMTase activity and Dnmt1 expression was measured from nuclear extract obtained by using the EpiQuik Nuclear Extraction Kit
I (Euromedex, France). Immunoprecipitations are performed by using the Catch and ReleaseH v2.0 Reversible Immunoprecipitation System (Millipore,
France). (B) Use of proximity ligation in situ assay (P-LISA) to monitor the disruption of the Dnmt1-PCNA interactions. Nucleus/DNA are in blue and
Dnmt1-PCNA interaction in red. Quantification was performed from the analysis of 100 cells of three independent experiments.
doi:10.1371/journal.pone.0011333.g002
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(Figure 4C). Despite the weak quantity of Dnmt1 immunopre-
cipitated by using the pDnmt1
S127 or pDnmt1
S143 antibodies, our
data clearly indicated that these two forms of Dnmt1 are devoid of
interaction with PCNA and UHRF1, but conserved their
interactions with HDAC1 (Figure 4C).
Thus, these two last results strongly demonstrated that the Akt/
PKC phosphorylation of Dnmt1 is a hallmark dictating whether
the Dnmt1 interact or not with PCNA and/or UHRF1
interactions. Besides, this results is consistent with the fact that
the Akt- and PKC-mediated phosphorylations of Dnmt1 occur in
regions included or juxtaposed the interaction domains of Dnmt1
with PCNA or UHRF1 [6,7,9]. The use of the pDnmt1
S127 and
pDnmt1
S143 antibodies also confirmed the fact that the Akt/PKC
phosphorylation of Dnmt1 is a hallmark dictating whether the
Dnmt1 interact or not with PCNA and/or UHRF1 interactions
since we observed a correlation between the level of phosphor-
ylation of Dnmt1 in PCTC used in figures 3A and 3B and the level
of the Dnmt1/PCNA/UHRF1 interactions in these cells (Sup-
plemental data S9). Thus, all these experiments indicated and
reinforced the idea that the increase of the presence of
pDnmt1
S127 and/or pDnmt1
S143 is performed to the detriment
of the presence of the Dnmt1/PCNA/UHRF1.
pDnmt1
S127/S143 and/or pDnmt1
S127 catalyze low mMTase
activity in comparison with Dnmt1/PCNA/UHRF1 and is
hallmark associated with poor prognosis in glioma
To determine whether the presence of the pDnmt1
S127 and/or
pDnmt1
S127/S143 to the detriment of the presence of the Dnmt1/
PCNA/UHRF1 is a situation associated with the decrease of the
mMTAse activity catalyzed by the Dnmt1, we next measured the
Figure 3. The disruption of the Dnmt1/PCNA/UHRF1 interactions is associated with the phsphorylation of Dnmt1 by Akt and/or
PKC. (A) Visualization, in primary cultured tumor cells (PCTC) of different grade of glioma, of the phosphorylation level of Dnmt1 by using antibodies
recognizing the phospho-(Ser/Thr) Akt substrate (pDnmt1-PAS, Ozyme, Cell Signal#9614, France) and the the phospho-(Ser) PKC substrate (pDnmt1-
PPCS, Ozyme, Cell Signal#2261, France). (B) Effect of the Akt and PKC inhibition on the phosphorylation level of Dnmt1, the Dnmt1-PCNA-UHRF1
interactions and on the mMTAse activity. (Akt
i: 0.1 mM Calbiochem#124005, France; PKC
i or Go6893, 0.5 mM Calbiochem#124005, France). (C) Effect
of the constitutive activation of Akt and PKC in Ntv-a/PDGF cells on the phosphorylation level of Dnmt1, the Dnmt1-PCNA-UHRF1 interactions and on
the mMTAse activity.
doi:10.1371/journal.pone.0011333.g003
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S127/S143,
the pDnmt1
S127, the Dnmt1 in presence of PCNA (Dnmt1-
PCNA), UHRF1 (Dnmt1-UHRF1) or PCNA and UHRF1
(Dnmt1-PCNA-UHRF1). As illustrated by the figure 5A,w e
noted that the phosphorylation of Dnmt1 by Akt or PKC in-
creased the mMTase activity of the Dnmt1 since pDnmt1
S127/S143
and pDnmt1S
127 catalyzed 4-fold more incorporation of methyl
group
3H-radiolabelled than the Dnmt1. Our analysis also
indicated that the mMTase activity of pDnmt1
S127/S143 and
pDnmt1S
127 are inferior to the mMTase activity catalyzed by
Dnmt1/PCNA (5-fold), Dnmt1/UHRF1 (4-fold) or Dnmt1/
PCNA/UHRF1 (9-fold). Thus, this data underline the existence
of a hierarchy of mMTase activity catalyzing by the Dnmt1 in
function its phosphorylation status and of its partners of
interaction. Besides, this hierarchy is consistent with our previous
results.
Our previous data indicating that the low mMTAse activity is a
poor prognosis factor, we now wondered whether the expression
level of pDnmt1
S127 and/or pDnmt1
S143 could be used as a
molecular marker of poor prognosis since the presence of these
Figure 4. The phsophorylation of the Dnmt1 at S127 and/orS143 decrease the capacity of the protein to interact with PCNA and
UHRF1. (A) Schematic representation of the Akt and PKC-induced phosphorylation of Dnmt1 according to the results obtained by mass
spectrometric approach. (B) Effect of the phosphorylation of the recombinant Dnmt1 (Methylation Ltd, Port Orange, Florida) by Akt and PKC on the
Dnmt1-PCNA, Dnmt1-UHRF1 and Dnmt1-HDAC1 interactions. Pull-down assays were performed by using the GST/His Tag Protein Interaction Pull-
Down Kits (Thermo Scientic, France). Fusion protein purification gel is illustrated in Supplemental data S5. The phoshorylation level of the Dnmt1
interacting with GST-PCNA, GST-UHRF1 and GST-HDAC1 was analyzed by ELISA method. Ct+: Dnmt1
R phosphorylated by Akt and/or PKC, Ct-:
Dnmt1
R.( C) Western blot analyses were realized to monitor the expression level of Dnmt1, pDnmt1
S127, pDnmt1
S143 and HDAC1, Actin was used as
control. IP experiments were realized by using the Catch and ReleaseH v2.0 Reversible Immunoprecipitation System (Millipore, France) with 4 mgo f
antibody. Western blot of IP experiments illustrate the results obtained by adding the immunoprecipitate obtained from 3 immunoprecipitations
performed with 500 mg of proteins.
doi:10.1371/journal.pone.0011333.g004
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mMTAse activity. In 16 GBM expressing similar level of Dnmt1,
we noted that the levels of pDnmt1
S127 and/or pDnmt1
S143 were
inversely correlated with the level of mMTase harbored by the
corresponding GBM (Pearson’s correlation test, r=20.535,
p=0.0327; r=20.531, p=0.0343) (Figure 5B).
Thus, these two results strongly support the idea that the
pDnmt1
S127 and pDnmt1
S127/S143 is less efficient to catalyze the
mMTase activity. In addition to being correlated with a low
mMTase activity, Kaplan-Meier method and Cox proportional
hazards survival regression analysis also revealed that the presence
of the pDnmt1
S127 and/or pDnmt1
S127/143 is associated with a
poor prognosis factor (p=0.0053) (Figure 5C). Thus, the
detection of the pDnmt1
S127 and/or pDnmt1
S143 in GBM appears
as a promising molecular biomarker that could be used as an
alternative predictor of disease outcome.
The disruption of the Dnmt1/PCNA/UHRF1 interactions
promotes the global DNA hypomethylation in astrocytes
(Astro#40) and in glial precusor cells (Ntv-a)
We then asked whether the disruption of these interactions, as a
single event, could generate the global DNA hypomethylation in
Astro#40 (astrocytes) and/or Ntv-a (glial precursors) cells. For this
purpose, we have transfected Astro#40 cells and Ntv-a cells with
pUP plasmid, i.e. a plasmid coding amino-acid regions of Dnmt1
(163–173aa) and UHRF1 (596–614aa) interacting with Dnmt1
[6,7,9] (Supplemental data S10). Dnmt1-immunoprecipitation
and P-LISA strongly demonstrated that the Dnmt1-PCNA-
UHRF1 interactions were disrupted in Astro#40/pUP and Ntv-
a/pUP cells (Figures 6A and 6B). ELISA revealed that the latter
cells displayed a lower level of 5 mC than its parental cells
(p,0.0001) (Figure 6A). By performing Chromatin Immunopre-
cipitation (ChIP) and Methylated DNA collection (MeDCO), we
noted that the transfection of Astro#40 and Ntv-a cells with the
pUP plasmid decreased the co-recruitment of Dnmt1, PCNA and
UHRF1 on Alu, a DNA repeat element, and reduced its degree of
methylation (Figures 6C and 6D). Thus, our data clearly
identify that the forced disruption of the Dnmt1/PCNA/UHRF1
interactions as a molecular determinant of global DNA hypo-
methylation.
The disruption of the Dnmt1/PCNA/UHRF1 interactions,
in astrocytes (Astro#40) and in glial precusor cells (Ntv-
a), promotes chromosomal instability and gene-specifc
hypomethylation
Hypomethylation of DNA repeat element being able to
induce chromosomal instability, we next performed a compar-
ative genome hybridization array (CGH-array) using DNA from
Astro#40/pCt and Atrso#40/pUP cells [10,11]. Significant
changes in chromosomes organization of Astro#40/pUP cells
Figure 5. pDnmt1
S127/S143 and/or pDnmt1
S127 catalyze low mMTase activity in comparison with Dnmt1/PCNA/UHRF1 and is
hallmark associated with poor prognosis in glioma. (A) Analysis of the mMTAse activity catalyzed by the Dnmt1, the Akt-mediated
phosphorylation of the Dnmt1 (pDnmt1-PAS), the PKC-mediated phosphorylation of the Dnmt1 (pDnmt1-PPCS), in presence of equimolar quantity of
PCNA, (Dnmt1-PCNA), or UHRF1 (Dnmt1-UHRF1) or PCNA and UHRF1 (Dnmt1-PCNA-UHRF1). mMTAse activities were assessed by DMB assay
according to Yokochi and Robertson (2004). (B) Correlation study between the mMTase activity and the expression level of pDnmt1
S127 and
pDnmt1
S143 harbored by 16 GBM. # represents grade IV astrocytomas/GBM. (C) Kaplan-Meier estimates time of survival between patients suffering
from glioma presenting a high expression level of pDnmt1
S127 and pDnmt1
S143 (grey line) and those whose tumors harbored a low expression level
of pDnmt1
S127 and pDnmt1
S143 (black line).
doi:10.1371/journal.pone.0011333.g005
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PLoS ONE | www.plosone.org 7 June 2010 | Volume 5 | Issue 6 | e11333Figure 6. The disruption of the Dnmt1/PCNA/UHRF1 interactions promotes the global DNA hypomethylation in astrocytes
(Astro#40) and in glial precusor cells (Ntv-a). (A) Monitoring by immunoprecipitation of Dnmt1 and ELISA of the effect of the expression of the
UP protein’’ (a chimera protein composed by the 163–171 amino-acids of PCNA and the 526–614 amino-acids of UHRF1) on the Dnmt1/PCNA/UHRF1
interactions and on the level of 5-methylcytosine (5 mC). (B) Use of proximity ligation in situ assay (P-LISA) to monitor the ‘‘UP’’-induced disruption of
the Dnmt1-PCNA interactions. Nucleus/DNA are in blue and Dnmt1-PCNA interaction in red. Quantification was performed from the analysis of 100
cells of three independent experiments. (C) Impact of the ‘‘UP’’-induced disruption of the Dnmt1-PCNA-UHRF1 interactions on the co-recruitment of
Dnmt1, PCNA and UHRF1 on Alu, a DNA repeat element. Chromatin Immunoprecipitation (ChIP) was performed by using the EZ-ChIP (Millipore,
France). For each point, the relative quantity of immunoprecipitated DNA is obtained by using input as reference. (D) Impact of the ‘‘UP’’-induced
disruption of the Dnmt1-PCNA-UHRF1 interactions on the methylation status of Alu by coupling the Methylated DNA COllection and PCR
amplification (MeDCO) via the use of the MethylCollector Ultra kit (Active Motif, France). (I:input: M:Methylated and collected DNA).
doi:10.1371/journal.pone.0011333.g006
DNA Methylation and Glioma
PLoS ONE | www.plosone.org 8 June 2010 | Volume 5 | Issue 6 | e11333compared to parental cells were observed such as 9 deletions
and 16 amplifications of specific chromosomal regions
(Figure 7A).
We extended our study by investigating the impact of the global
DNA hypomethylation on the methylation status of specific genes
since DNA hypomethylation has the potentially to activating
Figure 7. The disruption of the Dnmt1/PCNA/UHRF1 interactions, in astrocytes (Astro#40) and in glial precusor cells (Ntv-a),
promotes chromosomal instability and gene-specifc hypomethylation. (A) Description of chromosomal changes in Astro#40-UP cells via
the realization of CGH array. (B) Description of changes in the methylation profil Astro#40-UP cells via the realization of Methylation Array (Ozyme-
Panomics, France). (C) Validation by Methylated DNA Immunoprecipitation (MeDIP) and PCR amplification (MeDIP) of the hypomethylation of the
MGMT, PDGF-B, H-ras and survivin genes in Astro40#UP cells. (I:input: M:Methylated and collected DNA). For each point, the relative quantity of
immunoprecipitated DNA is obtained by using input as reference. (D) Expression level of the MGMT, PDGF-B, H-ras and survivin proteins in Astro#40
and Astro40#UP cells via western blot analysis.
doi:10.1371/journal.pone.0011333.g007
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gene-specific methylation profiles obtained by Promoter Methyl-
ation Array (Ozyme, France) revealed that the decrease of 5 mC
number in Astro#40/pUP cells as compared with that of
Astro#40/pCt cells is accompanied by the hypomethylation of
29 genes (Figure 7B). Among the hypomethylated genes,
MeDCO analysis validated the fact that, PDGF-B, H-ras, survivin
or MGMT genes were hypomethylated in Astro#40/pUP cells by
comparison with the Astro#40 cells (Figure 7C and Supple-
mental data S11). Finally, western blot indicated that the
hypomethylation of these genes is associated with their overex-
pression at protein level (Figure 7D). Similar results are also
obtained by analyzing the Ntv-a/pCt and Ntv-a/pUP cells
(Supplemental data S12).
Collectively, our data indicated that the disruption of the
Dnmt1-PCNA-UHRF1 interactions is a molecular event inducing
chromosomal instability and hypomethylation-initiated overex-
pression of oncogenes such as PDGF or H-ras.
The disruption of the Dnmt1/PCNA/UHRF1 interactions
promotes the tumor transformation of astrocytes
(Astro#40) and glial precusor cells (Ntv-a)
To determine whether the disruption of the Dnmt1/PCNA/
UHRF1 interactions can promote the tumor transformation of
Astro#40 and Ntv-a cells, we firstly investigated whether these
cells acquired some hallmark of cancer after their transfection by
the pUP plasmid. As illustrated by the figure 8A, we noted that it
was the case since the Ntv-a/pUP and Astro#40/pUP cells are
more proliferating and more resistant to temozolomide-induced
apoptosis than the Ntv-a/pCT and Astro#40/pCt cells. Secondly,
we have tested the tumorogenicity of the Ntv-a/pUP and
Astro#40/pUP cells in nude mice. Thus, tumorogenicity assay
performed via the s.c. injection of cells in nude mice showed that
the presence of macroscopically visible tumors in 100% (26/26)
injections of Ntv-a/UP cells, (Figure 8B), while no tumor pushes
after injections of Ntv-a cells. Similarly, we noted that the presence
of macroscopically visible tumors in 97% (34/35) injections of
Figure 8. Impact of the ‘‘UP’’-induced disruption of the Dnmt1/PCNA/UHRF1 interactions on hallmarks of cancer in Astro#40 and
Ntv-a cells. (A) Comparison of the temozolomide-induced apopto-sensitivity (via the measure of DEVDase activity) and the proliferation index
between the Astro#40 and Astro#40-UP cells and between the Ntv-a and Ntv-a/UP cells. DEVDase activity was assessed as previously described[33].
Proliferation index was evaluated by quantify the cells number. (B) Tumorigenicity test of the Ntv-a and Ntv-a/UP cells. (C) Comparison of the
tumorogenicity of the Ntv-a/UP cells with the one of the Ntv-a/PDGF and Ntv-a/Ras-Akt cells (left) and of the tumorogenicity of the Astro#40-UP cells
with the one of the primary cultured tumor cells (PCTC) obtained from low-grade glioma (LGG) or glioblastoma multiforme (GBM) (right). Pictures are
representative of tumors obtained after cells injection.
doi:10.1371/journal.pone.0011333.g008
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pattern of the tumors developed from the injection of Ntv-a/UP or
Astro#40-UP cells with the one developed from the injection of
the Ntv-a/PDGF (grade II glioma), Ntv-a/Ras-Akt (grade IV
glioma), PCTC#II, and PCTC#IV. As illustrated by the
figure 8C, it appears that the growth pattern of tumors developed
from the injection of Ntv-a/UP or Astro#40-UP cells are similar
to the ones obtained from the injection of cells of grade IV glioma
(i.e. Ntv-a/Ras-Akt or PCTC#IV cells). Thus, all these results
clearly demonstrate that the disruption of the Dnmt1/PCNA/
UHRF1 interactions acts as an oncogenic event inducer of
gliomagenesis.
In summary, our results underline, for the first time, that the
disruption of the Dnmt1/PCNA/UHRF1 interactions can be
associated with the Akt and/or PKC-mediated phosphorylation of
Dnmt1, and that this disruption acts as an oncogenic event inducer
of gliomagenesis by promoting the global DNA hypomethylation,
which play an important part in chromosomal alteration and in
the activation of proto-oncogene(s) by local hypomethylation (such
as PDGF-B, H-ras and MGMT genes) (Figure 9).
Discussion
Several papers demonstrate that PCNA and/or UHRF1 play a
crucial role in the recruitment and/or the anchorage of Dnmts on
DNA to maintain the DNA methylation pattern of mammalian
cells via the capacity of these proteins to bind DNA and hemi-
methylated DNA [6,8,12,13,14]. This work is the first or one of
the first to identify the disruption of the Dnmt1, PCNA and
UHRF1 interactions as a crucial oncogenic event promoting the
DNA hypomethylation-induced tumorigenesis. Indeed, to date,
the other model in which the DNA global hypomethylation
promoted the tumorigenesis implicates the reduction of the Dnmt1
expression to 10% of wild-type levels in mice carrying a
hypomorphic DNA methyltransferase 1 (Dnmt1) allele [10,15].
Nevertheless, despite the central roles of the DNA methyltrans-
ferases in the establishment and the maintenance of epigenetic
control, there was no evidence for the reduction of their expression
as a significant contributing factor for cancer-associated hypo-
methylation [5,16]. In our study, no Dnmt1 deficiency was
observed in 9 primary cultured tumor cells and in 82 different
Figure 9. Schematic representation of gliomagenesis induced by the disruption of the Dnmt1-PCNA-UHRF1 interactions.
doi:10.1371/journal.pone.0011333.g009
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frequent molecular determinant to the disruption of the Dnmt1-
PCNA-UHRF1, contrary to the phosphorylation of Dnmt1 at
serine-127 and/or at serine-143 by the Akt and PKC kinases.
Indeed, mass spectrometry analysis, pull down assay and the
synthesis of pDnmt1
S127 and pDnmt1
S143 antibodies validated the
fact that these two kinases play a crucial role in the formation/
disruption of the Dnmt1-PCNA-UHRF1 interactions and suggest
that the use of these antibodies could be used as an alternative
predictor of disease outcome since the high level of pDnmt1
S127
and pDnmt1
S143 in GBM seems to be associated with a poor
prognosis factor of survival. Besides, this last point and the search
of other mechanisms explaining the disruption of these interac-
tions are two ongoing subjects of study in our lab (referred as ‘‘X
event’’ in figure 9).
Moreover, the existence of (a) molecular mechanism(s) inhibit-
ing the Dnmt1/PCNA/UHRF1 interaction is also supported by
the paradoxical situation seen in astrocytoma cells. Indeed, the
astrocytoma cells harbor a low level of Dnmt1/PCNA/UHRF1
interaction, whereas these cells, highly proliferative, are supposed
to harbor a high level of the Dnmt1/PCNA/UHRF1 interaction
according to the idea that the maintenance DNA methylation is a
DNA replication-dependent process [17,18]. In addition, this
point participates to the debate to know the kinetic of the
chromatin loading of Dnmt1 during the different phases of the cell
cycle. Indeed, literature illustrates the debate by reporting, for
example, that HDAC2 joins Dnmt1 and DMAP1 only during late
S phase, that the association of Dnmt1 with the replication
machinery enhances methylation efficiency, but is not strictly
required for maintaining global methylation suggesting that the
recruitment of Dnmt1 on DNA is DNA replication-independent,
or against that the Dnmt1 is continuously loaded onto chromatin
throughout the G2 and M phases [19,20,21,22]. In our case, we
noted that the reduction of cell in S phase (by a 10-fold factor) did
not affect the number of Dnmt1/PCNA interaction (Supple-
mental data S13). More investigations are an ongoing in our lab
and they need for taking into account the ‘‘available’’ of the
various proteins taking part into the recruitment on the chromatin
of Dnmt1 such as G9a, PCNA, UHRF1, HDAC1, or transcription
factors such as E2F1 whose the expression and/or the post-
translational modifications could be variable during the cell cycle
[6,7,17,23,24].
To explain the tumorigenic mechanism associated with the
genome hypomethylation induced by the disruption of the
Dnmt1/PCNA/UHRF1 interactions, we demonstrate that the
loss of these interactions is an event at the origin of the 1)
chromosomal instability induced by the hypomethylation of DNA
repeat element and 2) hypomethylation-mediated overexpression
of specific genes such as the PDGF-B, survivin, H-ras, and MGMT
genes i.e. genes coding for oncogenes or proteins participating to
the acquisition of hallmarks of cancer [25,26,27,28,29]. Thus,
these results clearly reinforce the causal link existing between the
genome hypomethylation and the chromosomal instability because
our results underline the presence of 9 deletions and 16
amplifications of chromosomal regions in hypomethylated As-
tro#40-UP cells. Interestingly, Astro#40UP cells are character-
ized by the deletion of the 18p11 and 14q32 chromosomal regions
and by the 12q amplification, i.e. by chromosomal aberrations
often observed in glioma [30,31]. These results also support the
idea that these regions contain oncogenes and/or tumor
suppressor genes involved in the control of gliomagenesis.
By showing that the induction of global DNA hypometylation is
an event able to induce the gliomagenesis from astrocytes
(Astro#40 cells) and precursor of glial cells (Ntv-a cells), our data
underline an oncogenic pathway common of mature and
immature cells. Thus, the development of anti-glioma therapy
targeting the limitation of the global DNA hypomethylation could
be a successful therapy because glioma recurrence is frequently
attributed to the resistance of stem cells or progenitors of glial cells.
Materials and Methods
ELISA
Microtiter plate was coated with capture antibody for overnight
at 4uC. After 3 washes in PBS/Tween buffer (PBS pH 7.2–7.4,
Tween-20, 0.05%), microtiter plate was blocked with 200 ml/well
of blocking buffer (PBS pH 7.2, 10% Fetal calf serum) for 30 min
at room temperature. After 3 washes in PBS/Tween buffer,
samples are incubated for overnight at 4uC. After 3 washes in
PBS/Tween buffer, detection antibody is incubated at the
concentration of 2 mg/ml in 100 ml blocking buffer for 1 h at
room temperature. Revelation is performed by incubating 50 ml/
well of alkaline phosphatase conjugated secondary antibody
diluted to 1:500 in blocking buffer at room temperature for 1 h.
Wells are then washed three times with PBS/Tween buffer and
once with diethanolamine buffer (10 mM diethanolamine,
0.5 mM MgCl2 (pH 9.5) prior to pNPP substrate (Santa Cruz)
addition in diethanolamine buffer to a final concentration of
1 mg/ml. Reaction is stopped by adding 0.1 M EDTA and read
on microtiter plate reader at OD 405/490.
Genetic and epigenetic analyses
DNA was extracted by using the QiaAmp DNA mini Kit
(Qiagen, France).
Array-CGH experiments were performed by PartnerChip
(Evry, France) using the Constitutional Chip 4.0 from Perkin
Elmer.
Methylation array is performed by using the Promoter
Methylation Array Kit according to the manufacturer’s instruc-
tions (Ozyme, France).
Methyl-DNA ImmunoPrecipitation (MeDIP) and Methyl-DNA
collection were performed by using the MeDIP kit
TM and the
MethylCollector Ultra kit according to the manufacturers’s
instructions (Diagenode, France and Active Motif, France,
respectively).
Methyltransferase activities were estimated by performing DMB
assay according to Yokochi and Robertson (2004).
Olink/Duolink
Cells were fixed with 4% paraformaldehyde in PBS pH 7.4 for
15 min at room temperature. Permeabilization is performed with
PBS containing 0.5% Triton 1006 4 for 20 min at room
temperature and staining were realized according to manufactur-
er’s instructions (Olink Bioscience). Fluorescence was visualized
with ApoTome. 3D view was obtained by using Amira.4.1.1
program.
Tumorogenicity assay
Cultured cells were harvested by trypsinization, washed and
resuspended in saline buffer. Cell suspensions were injected s.c. as
10
6 cells in 0.2 ml volume in the flank of 7/8-week-old Nude
NMRI-nu female mice (Janvier, France).
Preparation of Astro#40-UP cells
Astro#40 cells come from the Clonexpress Inc (Gaithersburg,
USA). Ntv-a cells are a gift of Dr E.C. Holland. Astro#40-UP and
Ntv-a/UP cells were obtained after nucleofection by using the
Mouse Astrocyte Nucleofector
TM kit (Amaxa biosystems, France)
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obtained from Clonexpress Inc (Gaithersburg, USA).
Ethics statement
Human samples were collected according to French laws and
the recommendations of the French National Committee of
Ethics. The samples and the medical history of patients were
encoded to protect patient confidentiality and used under
protocols approved by the recommendations of the French
National Committee of Ethics.
The experimental procedures using animals were in accordance
with the guidelines of Institutional Animal Care and the French
National Committee of Ethics.
Supplemental experimental procedures
The Supplemental experimental procedures (Supplemental
data S14) include lists of antibodies and primers used in all
experiments and supplemental protocols.
Supporting Information
Data S1 Characteristics of patients presenting low maintenance
methyltransferase (mMTase) activity and High mMTase activity.
Found at: doi:10.1371/journal.pone.0011333.s001 (0.11 MB TIF)
Data S2 Determination of the 5mC number in indicated cells by
using flow cytometry method according to Hervouet et al. (Clin
Cancer Res., 2009).
Found at: doi:10.1371/journal.pone.0011333.s002 (0.03 MB TIF)
Data S3 Illustration of the control of the Dnmt1-immunopre-
cipitation performed by using the Catch and ReleaseH v2.0
Reversible Immunoprecipitation System (Millipore, France).
Found at: doi:10.1371/journal.pone.0011333.s003 (0.03 MB TIF)
Data S4 Effect of the farnesylthiosalicylic acid (FTS) (40 mM)
treatment on the mMTase activity in Ntv-a/PDGF cells.
Found at: doi:10.1371/journal.pone.0011333.s004 (0.03 MB TIF)
Data S5 SDS-PAGE and SyproRuby staining (in vitrogen,
France) illustrating the fusion protein purification.
Found at: doi:10.1371/journal.pone.0011333.s005 (0.05 MB TIF)
Data S6 Mass Spectrometry identification of PKC and AKT
phosphorylation sites on rhDnmt1. Trypsin-induced rhDnmt1
peptides were obtained following to rhDnmt1 in vitro phosphor-
ylation by PKC or Akt. Phosphopeptide enrichment was
performed by IMAC and peptides were analysed by LC-MS/
MS as described in Full Methods. MS spectra for the identified
phosphopeptides are shown in Fig. S5a. Two phosphopeptides
were identified in Akt-phosphorylated Dnmt1 (119–136 and 141–
156) (lower spectra), one of which was also identified in PKC-
phosphorylated Dnmt1 (119–136) (upper spectrum). Phosphopep-
tides were detected as 26and 36protonated peptides, as shown.
CID (collision induced dissociation) MS/MS analysis was
performed for both phosphopeptides on the 26 and 36
protonated species (MS/MS spectra recorded for the doubly
charged ions at 931.0 m/z for the 119–136 peptide and at
874.9 m/z for the 141–156 peptide are shown in Fig. S5b). These
spectra undoubtly revealed that only one serine residue is
phosphorylated on each peptide, namely S127 and S143. The
exact positioning of the phosphorylated serine could be evidenced
by the observed loss of 69Da, a signature of a dehydrated serine
after the loss of a phosphate group during the CID. In other terms,
MS/MS analysis undoubtly revealed that only one serine residue
is phosphorylated on each peptide, namely S127 and S143.
Phosphopeptides were detected as 26and 36charged peptides, as
shown for the first peptide. Of note, a minor peak corresponding
to 26charged peptide 119–136 could be detected in rh-Dnmt1.
Nevertheless, it is obvious that this peptide, even if present in the
control pool of tryptic peptides, is very minor since the intensity of
the peak is comparable to that of non-phosphorylated peptides
which were unspecifically bound by the IMAC. Besides, only the
26 charged peptide was detectable out of the background,
contrary to the in-vitro phosphorylated conditions.
Found at: doi:10.1371/journal.pone.0011333.s006 (0.19 MB TIF)
Data S7 Validation by ELISA method of the specificity of the
pDnmt1
S127 and pDnmt1
S143 antibodies. Unphosphorylated
recombinant Dnmt1 and Akt/PKC-mediated phosphorylated
recombinant Dnmt1 were used to validate the pDnmt1
S127 and
pDnmt1
S143 antibodies. The validation was confirmed by the fact
that the pre-incubation of unphosphorylated peptides (P1-unP
and P2-unP) not affected the detected of the pDnmt1, while
the pre-incubation of the phosphorylated peptides (P1-P and
P2-P) abrogated the detection of the pDnmt1. P1:
RTPRRSKSDGEAKPEP and P2: MADANSPPKPLSKPRT
phospho-serines are in bold.
Found at: doi:10.1371/journal.pone.0011333.s007 (0.05 MB
TIF)
Data S8 Validation by western blot analysis of antibodies
directed against the pDnmt1
S127 and pDnmt1
S143. Recombinant
Dnmt1 was phosphorylated as described in materials and methods
section previous to be used as sample in western blot analysis.
Found at: doi:10.1371/journal.pone.0011333.s008 (0.04 MB
TIF)
Data S9 Expression of the pDnmt1
S127 and pDnmt1
S143 in
PCTC using in figure 3A (A) and 3B (B). Ct-: negative control,
Ct+: recombinant Dnmt1 phosphorylated by PKC or Akt.
Found at: doi:10.1371/journal.pone.0011333.s009 (0.06 MB TIF)
Data S10 A: Position of primers and length of PCR products
obtained after amplification of void vector or integrated UP insert.
B: Detection of the integration of insert/constructs in vector and in
Ntv-a cells using PCR. C: GFP expression after pCt or pUP
nucleofection in Ntv-a. Similar data are obtained with the
Astro#40 cells.
Found at: doi:10.1371/journal.pone.0011333.s010 (0.13 MB
TIF)
Data S11 Impact of the UP-induced disruption of the Dnmt1-
PCNA-UHRF1 interactions on the methylation status of Alu by
coupling the Methylated DNA COllection and PCR amplification
(MeDCO) via the use of the MethylCollector Ultra kit (Active
Motif, France). (I:input: M:Methylated and collected DNA).
Found at: doi:10.1371/journal.pone.0011333.s011 (0.03 MB
TIF)
Data S12 Expression level of the MGMT, PDGF-B, H-ras and
survivin proteins in Ntv-a and Ntv-a/UP cells via western blot
analysis.
Found at: doi:10.1371/journal.pone.0011333.s012 (0.03 MB TIF)
Data S13 Cell cycle and Dnmt1-PCNA interaction. U251 cells
were synchronised or not by serum starvation (72 h). Cell cycle
phases were determined by using the NucleoCounter NC-
3000TM Kit (Chemometec, France) and Dnmt1/PCNA interac-
tion is determined by P-LISA method.
Found at: doi:10.1371/journal.pone.0011333.s013 (0.04 MB TIF)
Data S14 Supplemental experimental procedures.
Found at: doi:10.1371/journal.pone.0011333.s014 (0.06 MB
DOC)
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